Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | NCF1 | P14598 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24319406 | 0.88 | ALDH1A1 (0.37) | ALDH1A1KDM4ETDP1L3MBTL3L3MBTL1 | |
| SCHEMBL24480704 | 0.87 | KDM1A (0.37) | ALDH1A1NCF1KDM1ACACNA2D1CACNA1B | |
| SCHEMBL24481342 | 0.85 | NCF1 (0.32) | KDM4EL3MBTL1NCF1 | |
| SCHEMBL24204398 | 0.84 | NCF1 (0.41) | ALDH1A1KDM4ETDP1L3MBTL3L3MBTL1 | |
| SCHEMBL12772840 | 0.84 | NCF1 (0.39) | ALDH1A1KDM4ETDP1L3MBTL3L3MBTL1 | |
| SCHEMBL24204800 | 0.84 | NCF1 (0.43) | ALDH1A1KDM4ETDP1L3MBTL3L3MBTL1 | |
| SCHEMBL24351550 | 0.83 | NCF1 (0.37) | ALDH1A1KDM4ETDP1L3MBTL3L3MBTL1 | |
| SCHEMBL27267885 | 0.83 | KMT2A (0.37) | ALDH1A1KDM4ETDP1L3MBTL3L3MBTL1 | |
| SCHEMBL24204675 | 0.82 | NCF1 (0.42) | ALDH1A1KDM4ETDP1L3MBTL3L3MBTL1 | |
| SCHEMBL23875466 | 0.82 | SMN1; SMN2 (0.38) | ALDH1A1KDM4ETDP1L3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022012623-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2022-01-20 | — | — | WO | disclosed |